CAS 885692-52-4

JNJ-28312141

Description:

JNJ-28312141, with the CAS number 885692-52-4, is a chemical compound that has been investigated primarily for its potential therapeutic applications, particularly in the field of oncology. It is classified as a small molecule inhibitor, specifically targeting certain kinases involved in cancer cell proliferation and survival. The compound exhibits a unique structure that allows it to interact selectively with its biological targets, which may contribute to its efficacy in inhibiting tumor growth. In preclinical studies, JNJ-28312141 has shown promise in various cancer models, demonstrating the ability to induce apoptosis in cancer cells and inhibit tumor progression. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its suitability for clinical use. As with many investigational drugs, ongoing research is essential to fully understand its safety profile, optimal dosing regimens, and potential side effects. Overall, JNJ-28312141 represents a significant area of interest in the development of targeted cancer therapies.

Formula: C₂₆H₃₂N₆O₂

Synonyms:

• CS-2012
• 4-Cyano-N-(5-(1-(2-(dimethylamino)acetyl)piperidin-4-yl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl
• 4-CYANO-N-[2-(CYCLOHEX-1-EN-1-YL)-4-{1-[2-(DIMETHYLAMINO)ACETYL]PIPERIDIN-4-YL}PHENYL]-1H-IMIDAZOLE-2-CARBOXAMIDE
• 1H-Imidazole-2-carboxamide, 5-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]-4-piperidinyl]phenyl]-
• JNJ 28312141; JNJ28312141
• JNJ-28312141
• JNJ-28312141(JNJ-141)
• JNJ-28312141; JNJ28312141; JNJ 28312141.

JNJ-28312141

CAS: 885692-52-4

JNJ-28312141 is a potent, selective inhibitor of the receptor tyrosine kinase TIE2 for the treatment of malignant glioma. It has been shown to inhibit tumor growth and induce cell death in vivo in a number of preclinical models of cancer. JNJ-28312141 also inhibits angiogenesis and reduces inflammatory responses in tumor microenvironments. This drug binds to a unique site on TIE2 that is distinct from the binding site for zoledronate, which is used as an anti-angiogenic therapy. Treatment with JNJ-28312141 has been shown to have positive effects in animal models of bone lesions with mesenchymal markers, including assays that are based on kinase selectivity, growth factor receptor activation, or bone metabolism. The efficacy of JNJ-28312141 has been demonstrated in glioma patients who were undergoing surgery and had resection.
END>

Formula: C₂₆H₃₂N₆O₂

Purity: Min. 95%

Molecular weight: 460.57 g/mol

Ref: 3D-KKB69252

JNJ-28312141

CAS: 885692-52-4

JNJ-28312141: oral CSF1R/FLT3 inhibitor, potential for treating acute myeloid leukemia, tumors, and bone events.

Formula: C₂₆H₃₂N₆O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 460.57

Ref: TM-T21330